Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$349.10K$349.10K−71.9% vs Q1 2024 Net Income-$4.45M-$4.45MN/M vs Q1 2024 EPS Diluted-$0.40-$0.40N/M vs Q1 2024 Operating Income-$4,957,777N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1420.1%−1215.2 pt vs Q1 2024
Net margin-1273.6%−1081.3 pt vs Q1 2024
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end